MetaCap

Alterity Therapeutics (ATHE) vs NanoViricides (NNVC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NanoViricides (NNVC) has outperformed Alterity Therapeutics (ATHE) over the past year, losing 10.2% versus a loss of 56.7%. Over five years, NNVC leads with a -76.5% price change compared with -85.4% for ATHE. NanoViricides is the larger company by market cap ($29.1 million vs $29.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATHE-56.70%NNVC-10.24%
+74%+6%-63%
Nov 21, 20251 yearNov 20, 2026
ATHE-85.93%NNVC-75.16%
+11%-42%-95%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATHE versus NNVC key metrics
MetricATHENNVC
Share price$1.52$1.14
Market cap$29.02M$29.13M
1-day change-8.16%-2.56%
YTD return-50.65%+0.88%
1-year return-56.70%-10.24%
5-year return-85.38%-76.54%
EPS (TTM)$-0.90$-0.53
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)—$-8.22M
52-week high$5.89$1.93
52-week low$1.52$0.85
Distance from 52-week high-74.19%-40.93%
Analyst consensusnonestrong_buy
Avg. price target upside+771.71%+426.32%
Average volume89.63K356.86K
Shares outstanding19.09M25.55M
Employees117
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NNVC has outperformed ATHE by 46.5 percentage points over the past year.

About Alterity Therapeutics

ATHE stock →

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees

About NanoViricides

NNVC stock →

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

ATHE vs NNVC FAQ

Which is bigger, Alterity Therapeutics or NanoViricides?

NanoViricides (NNVC) is larger, with a market capitalization of $29.13M compared with $29.02M for Alterity Therapeutics (ATHE).

Which stock has performed better over the past year, ATHE or NNVC?

NNVC returned -10.24% over the past 12 months, compared with -56.70% for ATHE (price return, excluding dividends). Past performance does not predict future results.

Are Alterity Therapeutics and NanoViricides in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons